Appeal No. 1996-2784
Application No. 08/069,069
(a) admitting orally into the human a dosage
form comprising 10 nanograms to 750 milligrams
of an antiepileptic drug selected from the group
con-sisting of valproic acid, valproic acid
salts, sodium valproate, potassium valproate,
calcium valproate, valpromide, valproic ester,
divalproex sodium, oligomer salt of valproic
acid, prodrug of valproic acid, and
pharmaceutically acceptable derivatives of
valproic acid; which drug possess-ing
antiepileptic therapy is administered from a
dosage form comprising a member selected from
the group consisting of a sustained-release
dosage form and a controlled-release dosage
form; and,
(b) administering the antiepileptic drug from
the dosage form over a therapeutic dose up to
750 mg over an extended period of time up to 30
hours to provide the antiepileptic therapy.
7. A method for administering an antiepileptic drug to
the gastrointestinal trace of a human, wherein the method
comprises:
(a) admitting orally into the human a dosage
form comprising 10 nanograms to 750 milligrams
of a member selected from the group consisting
of one to three moles of valproic acid and one
to six moles of a salt of valproic acid; an
oligomer of valproic acid salt, and valproic
acid containing four moles of the salt and the
acid; three moles of valproic acid and calcium
valproate; valproic acid and sodium valproate;
valproic acid and divalproex sodium and calcium
valproate and valpromide; which drug possessing
antiepileptic therapy is administered from a
dosage form comprising a member selected from
the group consisting of a sustained-release
2
Page: Previous 1 2 3 4 5 6 7 Next
Last modified: November 3, 2007